World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
111
Citations
42919
World Ranking
5353
National Ranking
297

Kristian Reich publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Kristian Reich sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 596 publications — 71st percentile

71% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Kristian Reich D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Kristian Reich sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 111 D-Index — 74th percentile

74% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Kristian Reich is a researcher affiliated with the University of Göttingen in Germany. Their work primarily focuses on the fields of medicine, immunology, and dermatology, with a research portfolio that bridges immunology and microbiology. Reich's subfields include immunology, immunology and allergy, dermatology, rheumatology, and physiology.

The research topics they address cover a broad spectrum related to skin and immune system diseases, particularly:

  • Psoriasis: Treatment and Pathogenesis
  • Dermatology and Skin Diseases
  • Asthma and respiratory diseases
  • Autoimmune Bullous Skin Diseases
  • Allergic Rhinitis and Sensitization
  • Health Systems, Economic Evaluations, Quality of Life
  • Pharmaceutical studies and practices

Kristian Reich has published extensively, with a significant number of works appearing in highly regarded dermatology and medical journals. Frequent publication venues include:

  • Journal of the American Academy of Dermatology
  • British Journal of Dermatology
  • Journal of the European Academy of Dermatology and Venereology
  • SKIN The Journal of Cutaneous Medicine
  • Journal of Investigative Dermatology

The scientist has collaborated regularly with other prominent researchers in the field. Frequent co-authors include:

  • Andrew Blauvelt
  • Richard G. Langley
  • Richard B. Warren
  • Mark Lebwohl
  • Matthias Augustin

Among Kristian Reich's recent publications are several notable papers such as:

  • Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial (2021, The Lancet)
  • Bimekizumab versus Secukinumab in Plaque Psoriasis (2021, New England Journal of Medicine)
  • Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial (2021, The Lancet)

These publications focus on clinical trials and therapeutic advancements targeting skin conditions such as atopic dermatitis and plaque psoriasis. The work involves randomized controlled studies assessing safety and efficacy of novel treatments.

Best Publications

  • Secukinumab in plaque psoriasis--results of two phase 3 trials.

    Richard G. Langley;Boni E. Elewski;Mark Lebwohl;Kristian Reich

  • Infliximab induction and maintenance therapy for moderate-to-severe psoriasis : a phase III, multicentre, double-blind trial

    Kristian Reich;Frank O Nestle;Kim Papp;Jean-Paul Ortonne

  • Definition of treatment goals for moderate to severe psoriasis: a European consensus

    U. Mrowietz;K. Kragballe;K. Reich;P. Spuls

  • European S3-guidelines on the systemic treatment of psoriasis vulgaris

    D Pathirana;AD Ormerod;P Saiag;Catherine Smith

  • Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

    Christopher E M Griffiths;Kristian Reich;Mark Lebwohl;Peter van de Kerkhof

  • Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.

    Kristian Reich;April W. Armstrong;Peter Foley;Michael Song

  • Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

    Kim Papp;Kristian Reich;Craig L. Leonardi;Leon Kircik

  • Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial

    Diamant Thaçi;Andrew Blauvelt;Kristian Reich;Tsen-Fang Tsai

  • Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

    Kristian Reich;Kim A Papp;Andrew Blauvelt;Stephen K Tyring

  • Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey

    Mark G. Lebwohl;Hervé Bachelez;Jonathan Barker;Giampiero Girolomoni

  • Epidemiology and comorbidity of psoriasis in children

    M. Augustin;G. Glaeske;M.A. Radtke;E. Christophers

  • Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ)

    M. de Bruin-Weller;D. Thaçi;C.H. Smith;K. Reich

  • European S3‐Guidelines on the systemic treatment of psoriasis vulgaris – Update 2015 – Short version – EDF in cooperation with EADV and IPC

    A Nast;P Gisondi;A D Ormerod;P Saiag

  • Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up.

    K A Papp;C E M Griffiths;K Gordon;M Lebwohl

  • Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis

    K. Reich;K. Krüger;R. Mössner;M. Augustin

  • A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis†

    K.A. Papp;K. Reich;C. Paul;A. Blauvelt

  • Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase.

    Marcus Maurer;Sabine Altrichter;Thomas Bieber;Tilo Biedermann

  • S3 – Guidelines on the treatment of psoriasis vulgaris (English version). Update

    Alexander Nast;Wolf-Henning Boehncke;Ulrich Mrowietz;Hans-Michael Ockenfels

  • Co-morbidity and age-related prevalence of psoriasis: Analysis of health insurance data in Germany.

    Matthias Augustin;Kristian Reich;Gerd Glaeske;Ines Schaefer

  • A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.

    Kenneth B. Gordon;Kristina Callis Duffin;Robert Bissonnette;Jörg C. Prinz

Frequent Co-Authors

Ulrich Mrowietz
Ulrich Mrowietz Kiel University
Matthias Augustin
Matthias Augustin Universität Hamburg
Kim Papp
Kim Papp Probity Medical Research
Andrew Blauvelt
Andrew Blauvelt Veterans Health Administration
Diamant Thaçi
Diamant Thaçi University of Lübeck
Richard G. Langley
Richard G. Langley Dalhousie University
Christopher E.M. Griffiths
Christopher E.M. Griffiths University of Manchester
Mark Lebwohl
Mark Lebwohl Icahn School of Medicine at Mount Sinai
Carle Paul
Carle Paul Federal University of Toulouse Midi-Pyrénées
Craig L. Leonardi
Craig L. Leonardi Saint Louis University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students considering alternative routes into healthcare, pursuing online degrees can be a flexible and cost-effective solution. Whether you’re looking at entry-level roles or aiming for advanced practice, there are a wide range of programs available online.

If administrative healthcare appeals to you, medical coding certification cost is an important factor to consider. Acquiring certification online is often more affordable than in-person options, making it accessible to more students.

For those seeking clinical careers, exploring the how much is online nursing school question is crucial. Many online nursing programs provide flexible schedules without the high price tag of on-campus learning.

Aspiring nurse practitioners can compare the cheapest fnp programs to find affordable pathways to become a Family Nurse Practitioner, a highly respected role in the medical field.

For those interested in leadership or academia, pursuing phd nursing education online allows for advancing your credentials while maintaining work-life balance.

Best Scientists Citing Kristian Reich

Trending Scientists

Recently Published Articles